Aulos looks to Phase III for IL-2 mAb in NSCLC and melanoma
Aulos Bioscience’s cancer therapy, imneskibart, could enter a registrational study either in melanoma, non-small cell lung cancer (NSCLC) or both, …
Post
-
-
Dupixent set for ninth US approval after Phase III AFRS success
Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary …
-
Forced degradation studies: A critical lens into pharmaceutical stability
Forced degradation studies simulate harsh conditions to accelerate degradation, helping us uncover potential vulnerabilities in a molecule’s structure and predict …
-
Synthekine reports initial STK-012 data in lung cancer trial
Synthekine has reported positive initial data from a Phase Ia/Ib trial evaluating STK-012 in first-line, programmed death-ligand 1 (PD-L1)-negative nonsquamous …
-
Psyence BioMed doses multiple patients in adjustment disorder study
Psyence Biomedical (Psyence BioMed) has dosed multiple participants in its ongoing Phase IIb clinical study assessing nature-derived psilocybin alongside psychotherapy …
-
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial
A patient dosed with Intellia Therapeutics’ CRISPR gene therapy has died after suffering a severe liver-associated adverse event (AE). The patient …
-
Eledon takes transplant rejection therapy to Phase III on mixed results
Eledon Pharmaceuticals’ lead asset, tegoprubart, is going to late-stage trials in kidney transplant rejection prevention, despite missing its primary efficacy …
-
Lilly to advance alternative obesity candidate to Phase III
Eli Lilly is advancing its obesity treatment candidate, which is an alternative to glucagon-like peptide-1 receptor agonists (GLP-1RAs), to Phase …
-
Imbria randomises first subject in Phase IIb trial of nHCM therapy
Imbria Pharmaceuticals has randomised the first participant in FORTITUDE HCM, a Phase IIb trial of ninerafaxstat in symptomatic non-obstructive hypertrophic …
-
Study explores chronic health outcomes associated with polycystic ovary syndrome
The hormonal and metabolic disturbances associated with polycystic ovary syndrome (PCOS) are a risk factor for a variety of health …
-
WHO releases new report for paediatric clinical studies
The World Health Organization (WHO) has published a technical report establishing a global research agenda for paediatric clinical trials targeting …
-
Centessa’s stock recovers from drop on sleep drug data
Centessa Pharmaceuticals executives will be breathing a sigh of relief as its stock price recovered after a drop caused by …
-
MoonLake claws back HS potential for sonelokimab on teen trial results
MoonLake Therapeutics’ sonelokimab has posted a potential comeback in hidradenitis suppurativa (HS) following the positive results of a Phase III …
-
MMI wins IDE for surgical robotic Alzheimer’s disease study
US-based robotics company Medical Microinstruments (MMI) has obtained an investigational device exemption (IDE) from the US Food and Drug Administration …
-
Novo Nordisk’s oral Wegovy reduces cardiovascular risk factors in obesity
Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being used by the …
